Versant Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.05K Hold
148
– – ﹤0.01% 2547
2026
Q2
$2.72K Buy
148
+14
+10% +$226 ﹤0.01% 2528
2026
Q1
$2.62K Hold
134
– – ﹤0.01% 2521
2025
Q4
$4.17K Hold
134
– – ﹤0.01% 2316
2025
Q3
$2.89K Hold
134
– – ﹤0.01% 2346
2025
Q2
$1.87K Sell
134
-179
-57% -$2.43K ﹤0.01% 2394
2025
Q1
$4.22K Buy
313
+231
+282% +$3.94K ﹤0.01% 2083
2024
Q4
$1.57K Buy
+82
New +$1.78K ﹤0.01% 2106

Other funds holding VRDN

Versant Capital Management's VRDN Position: Q3 2026 in Review

Versant Capital Management held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 148 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

Versant Capital Management first reported a position in VRDN in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.22K in Q1 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Versant Capital Management held 148 shares of Viridian Therapeutics worth $3.05K as of Q3 2026.
  • Versant Capital Management left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2547 holding.
  • Versant Capital Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Versant Capital Management's Viridian Therapeutics position peaked at $4.22K in Q1 2025.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.